20/20 GeneSystems

Cancer is the second leading cause of death in the world, responsible for 14 million new cases in 2012 and 8.8 million deaths in 2015. However, early Detection of many cancers through screening drastically improves survival. In lung cancer, the #1 cancer killer, the 5-year survival rate for screen detected Stage 1 is better than 90% vs, less than 10% for Stage 4 when it is most commonly first diagnosed. The global cancer diagnostics market was valued at $7.1 billion in 2015 and is projected to reach $13.1 billion by the year 2020, increasing at a compound annual growth rate (CAGR) of 12.9% during this period. To accomplish our mission of improving cancer outcomes through early detection we develop and commercialize blood tests using innovative, proprietary, but reliable scientific methods. 20/20’s cancer tests measure and track the levels of protein “biomarkers” in the blood which tend to increase as tumors grow and spread. Importantly, the machines and biochemicals we use to measure these biomarkers are the same ones widely used by thousands of top tier medical testing laboratories worldwide thereby enhancing reliability and affordability through economies of scale. Furthermore, this permits us to capture data from thousands of others similarly tested and then follow-up to assess their health history one year after the test. This data is then used to build machine learning algorithms that have been demonstrated by 20/20 and our collaborators to improve diagnostic accuracy over biomarker testing alone. We believe we are the first company to utilize this technical approach.

$2,500: Two transferable multi-cancer or lung tests
$10,000: Six transferable multi-cancer or lung tests
$75,000: Twenty transferable multi-cancer or lung tests
$100,000: Lifetime of annual cancer screenings for a spousal pair
$200,000: All of the above plus an all-expenses paid trip (airfare and lodging) for one to Taiwan for a 2 day state-of-the-art platinum level medical checkup including OneTEST and a full battery of tests for all body systems.
$250,000: All of the above for two individuals
$500,000: All of the above for four individuals

Introducing OneTest™ this year — what we believe is the first multi-cancer early detection blood test powered by machine learning algorithms built with data from tens of thousands of individuals tested before being diagnosed with cancer
Backed by Ping An Ventures, the strategic investment arm of one of China's leading health insurance and digital health companies
7 issued patents with numerous patent applications pending worldwide
Awarded more than $6mm in government grants and contracts from the National Institutes of Health (NIH) in support of cancer diagnostic technologies
Previously tested over 3,500 individuals with its PAULA’s test for the early detection of lung cancer

We intend to use the net proceeds of this offering for sales and marketing, research and development, intellectual property development and protection, cybersecurity and patient privacy protection and working capital and other general corporate purposes. Pending such uses, we will invest the proceeds of the offering in short-term, interest-bearing, investment-grade securities, certificates of deposit or direct or guaranteed obligations of the United States. 

Jonathan Cohen - CEO
Under Mr. Cohen’s leadership, 20/20 GeneSystems has brought in approximately $6 million in grant funding and launched two successful products, a kit for suspicious powders used by hundreds of emergency responder organizations worldwide and a blood test for the early detection of lung cancer. As 20/20’s CEO, Mr. Cohen forged strategic alliances with Fortune 500 companies such as Johnson & Johnson, Eastman Kodak, Abbott Diagnostics, and Ping An Ventures, the investment arm of the largest insurance company in China. Before founding 20/20, Mr. Cohen was patent and general counsel for two publicly traded companies: Ventana Medical Systems Inc. (acquired by Roche diagnostics in 2008 for $3.4 billion) and Oncor Inc. Mr. Cohen had more than 18 years of experience in biotechnology patents and licensing matters. He has a Master of Science in Biotechnology from Johns Hopkins University and a law degree from the American University.

• Security Type: Preferred Equity
• Share price: US $3.5300
• Pre-money valuation: US $26,000,000
• Is participating?: Yes
• Liquidation preference: 1.0x
• Minimum investment: US $1,000
• Target Minimum: US $450,000